Gene expression profiling in frataxin deficient mice: Microarray evidence for significant expression changes without detectable neurodegeneration

Friedreich's ataxia (FRDA) is caused by reduction of frataxin levels to 5–35%. To better understand the biochemical sequelae of frataxin reduction, in absence of the confounding effects of neurodegeneration, we studied the gene expression profile of a mouse model expressing 25–36% of the normal...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Neurobiology of Disease
المؤلفون الرئيسيون: Giovanni Coppola, Sang-Hyun Choi, Manuela M. Santos, Carlos J. Miranda, Dmitri Tentler, Eric M. Wexler, Massimo Pandolfo, Daniel H. Geschwind
التنسيق: مقال
اللغة:الإنجليزية
منشور في: Elsevier 2006-05-01
الموضوعات:
الوصول للمادة أونلاين:http://www.sciencedirect.com/science/article/pii/S096999610500313X
الوصف
الملخص:Friedreich's ataxia (FRDA) is caused by reduction of frataxin levels to 5–35%. To better understand the biochemical sequelae of frataxin reduction, in absence of the confounding effects of neurodegeneration, we studied the gene expression profile of a mouse model expressing 25–36% of the normal frataxin levels, and not showing a detectable phenotype or neurodegenerative features. Despite having no overt phenotype, a clear microarray gene expression phenotype was observed. This phenotype followed the known regional susceptibility in this disease, most changes occurring in the spinal cord. Additionally, gene ontology analysis identified a clear mitochondrial component, consistent with previous findings. We were able to confirm a subset of changes in fibroblast cell lines from patients. The identification of a core set of genes changing early in the FRDA pathogenesis can be a useful tool in both clarifying the disease process and in evaluating new therapeutic strategies.
تدمد:1095-953X